AmphiStar SRL
13.5 FTEThe score of AmphiStar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +5107 % Total assets +2228 %
Accounts of the company itself (not consolidated).
The full file covers 4 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
AmphiStar's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 15 Jun 2026
- Year ended 31 Dec 2024filed on 15 Jul 2025
- Year ended 31 Dec 2023filed on 28 Jun 2024
- Year ended 31 Dec 2022filed on 13 Jul 2023
AmphiStar's financial analysis
- Solvency63.2%sector median: 61.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of AmphiStar
AmphiStar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0771.868.491
- VAT number
- BE0771868491
- Peppol
- Registered · 0208:0771868491 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 30 Jul 2021
- Registered office
- 9052 Ghent
- Size
- Small · 13.5 FTE
- Latest accounts
- 2025 · filed on 15 Jun 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
AmphiStar (SRL) has been based in Ghent since 2021, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of 129,746 € and equity of €6.40m; its revenue is not published. With 13.5 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 63.2%, above the median of its sector (61.7%).
Companies similar to AmphiStar
Companies in the same business, of comparable size and area, outside its group.
- EXO Biologics Research and experimental development on natural sciences and engineering Liège · balance sheet €11.7m
- Intrexon Actobiotics Research and experimental development on natural sciences and engineering Nazareth-De Pinte · balance sheet €8.76m
- Aboleris Holdco Research and experimental development on natural sciences and engineering Charleroi · balance sheet €14.8m
- ConvEyXo Research and experimental development on natural sciences and engineering Charleroi · balance sheet €10.3m
- AstriVax Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €12.5m
- The Akkermansia Company Research and experimental development on natural sciences and engineering Mont-Saint-Guibert · balance sheet €16.9m
- OSIVAX Belgique Research and experimental development on natural sciences and engineering Liège · balance sheet €17.0m
- Inbiose Manufacture of other chemical products n.e.c. Ghent · balance sheet €17.2m
Frequently asked questions about AmphiStar
What is the revenue of AmphiStar?
AmphiStar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of AmphiStar?
In Belgium, the VAT number is the company number prefixed with BE: BE0771868491 for AmphiStar, if the company is VAT-registered. Its company number (CBE) is 0771.868.491.
Where is the registered office of AmphiStar?
According to the CBE register, the registered office of AmphiStar is in 9052 Ghent.
What is the equity of AmphiStar?
At the close of the 2025 financial year, the equity of AmphiStar amounts to 6,401,348 €, a solvency of 63.2% of total assets.
How many people work at AmphiStar?
13.5 full-time equivalents on average according to the 2025 social balance sheet.
Who manages AmphiStar?
The register lists 10 active mandates at AmphiStar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of AmphiStar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →